Valved holding chambers are widely prescribed to assist patients receiving inhaled medications by avoiding losses caused by imperfect coordination of inhalation and actuation and also to reduce oropharyngeal deposition.
Regardless of whether using a solution based formulation (like Qvar) or a suspension formulation (Flovent), the use of a valved holding chamber reduced the amount of medication deposited in the mouth (oropharynx) and increased the potential for lung delivery
This study can be used to help demonstrate the value of using a valved holding chamber for both solution and suspension formulated metered dose inhalers and for all patient populations, including adults
The continuous involvement of patients resulted in a number of key insights that helped guide the design process, resulting in the development of a chamber that patients are much more likely to use while on-the-go.
The AeroChamber2go* Spacer has been honored with a GOOD DESIGN® Award, the world’s oldest and most prestigious design program. The unique 2-in-1 spacer and protective inhaler case has been recognized for its innovative design, which benefits patients, the healthcare system, and the environment.
Evaluations of inhaler use have demonstrated that mishandling of MDIs is commonplace.
One of the most common errors is the failure to coordinate inhalation with actuation of the inhaler
One of the reasons why VHCs are often prescribed, is to reduce the severity of this error
This Functional Respiratory Imaging (FRI) based study assessed the likely severity of a short inhalation delay (from actuation) with an MDI alone and how it contrasted to the use with a VHC
